BARDA DRIVe is seeking information on developments in anticoagulation drugs, assays, and management in the specific context of extracorporeal membrane oxygenation (ECMO) therapy. The intent is to identify areas of innovation that can solve the challenges posed by anticoagulation in ECMO or improve on the ways this issue is currently being addressed. BARDA will not execute any awards based on this notice. This RFI solely aims to gather knowledge on present and future capabilities and other pertinent marketplace data to strengthen BARDA’s understanding of the current developmental landscape of this field. This does not constitute a Request for Proposal (RFP).
All technical and administrative correspondence and questions regarding this announcement must be submitted via email to DRIVeContracting@hhs.gov by 11:00AM ET on April 13th, 2021 with the Subject Line: “[Company Name] DRIVe Anticoagulation in ECMO Therapy Questions to RFI”. Answers to relevant questions will be posted to the RFI on www.beta.sam.gov. Questions should not contain proprietary or classified information. BARDA DRIVe cannot guarantee that questions received after 11:00AM ET on April 13th, 2021 will be answered.